Abstract Background. Hepatitis C virus (HCV)–infected drug users (DUs) have largely been
excluded from HCV care. We conducted a systematic review and meta-analysis of the …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …

OBJECTIVE: To assess the effectiveness of treatment for hepatitis C virus (HCV) infection in
low-and middle-income countries and identify factors associated with successful outcomes …

In high income countries, the majority of new and existing hepatitis C virus (HCV) infections
occur among people who inject drugs (PWID). In many low and middle income countries …

In the developed world, the majority of new and existing hepatitis C virus (HCV) infections
occur among people who inject drugs (PWID). The burden of HCV-related liver disease in …

Gaps in hepatitis C virus (HCV) testing, diagnosis, liver disease assessment and treatment
uptake among people who inject drugs (PWID) persist. We aimed to describe the cascade of …

Objectives People who inject drugs (PWID) are at high risk for acquiring hepatitis C virus
(HCV), but many are unaware of their infection. HCV dried blood spot (DBS) testing …

Viral hepatitis affects more than 320 million people globally, leading to significant morbidity
and mortality due to liver failure and hepatocellular carcinoma (HCC). More than 248 million …

Opioid-induced immunosuppression has been demonstrated in cell culture experiments and
in animal models. This is in striking contrast to the paucity of confirmatory studies in humans …

Background Fifteen million adults in the World Health Organization European Region are
estimated to have active hepatitis C infection. Intravenous drug use is a major hepatitis C …